Tofacitinib, an oral Janus kinase inhibitor is found to be more effective against rheumatoid arthritis. It has been reported in tow independent trials published in August 9 issue. One of the trial even hints that drug could be as effective as parenteral TNF blockers.

Tofacitinib is a Janus kinase inhibitor. In one trial by Fleischmann and colleagues, it is reported that tofacitinib proved superior to placebo when used alone in patients with rheumatoid arthritis resistant to earlier treatments, including methotrexate or biological therapies like as tumor-necrosis factor inhibitors.

The other trial by van Vollenhoven and colleagues tofacitinib had results to superior to placebo and similar to adalimumab, a tumor necrosis factor blocker. [Read more...]